The role of monoamine oxidase inhibitors in current psychiatric practice
- PMID: 15552546
- PMCID: PMC2075358
- DOI: 10.1097/00131746-200407000-00005
The role of monoamine oxidase inhibitors in current psychiatric practice
Abstract
The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the past several decades with the expansion of psychiatrists' pharmacologic armamentarium. This trend has also been driven by concern about food and drug interactions and side effects, as well as waning physician experience with these medications. Many psychiatrists, in fact, never prescribe MAOIs. Recent research has liberalized the MAOI diet and identified symptom presentations more likely to respond to these medications. Thus, clinicians must continue to familiarize themselves with the properties of and indications for prescribing MAOIs.
References
-
- Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000;61:26–32. - PubMed
-
- Nutt D, Glue P. Monoamine oxidase inhibitors: Rehabilitation from recent research? Br J Psychiatry. 1989;154:287–291. - PubMed
-
- Petersen T, Dording C, Neault NB, et al. A survey of prescribing practices in the treatment of depression. Prog Neuro-psychopharmacol Biol Psychiatry. 2002;26:177–187. - PubMed
-
- Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry. 1993;150:571–577. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
